Home
 /
Papers
 /
Evolutionary Biology
 /
Biophysical trade-offs in antibody evolution are resolved by conformation-mediated epistasis
Preprint
Open access
Top 1% · Validated by QED

Biophysical trade-offs in antibody evolution are resolved by conformation-mediated epistasis

Cole R. Tharp, Claudio Catalano, Anthony Khalifeh +5 more
March 2026
 ·
bioRxiv
 ·
DOI 
10.64898/2026.03.12.711465
99
%
QED Score
QED Impressions

By establishing that antibody evolution navigates multidimensional biophysical trade-offs through rare, epistasis-dependent paths, this work overturns affinity-centric maturation models and introduces a human-cell platform that makes these constraints measurable and actionable for therapeutic antibody design.

Run full QED analysis
Read paper
Save

QED claims analysis

Summary

Antibody affinity maturation navigates multidimensional biophysical trade-offs between surface expression, antigen affinity, and self-reactivity through conformation-mediated epistasis, where conformational rearrangement of CDR loops creates specific mutational order requirements that enable accessible evolutionary pathways by alleviating steric clashes and preconfiguring the antibody for antigen binding.

See full analysis
Main Claim 1 –

Mutations Create Trade-offs Among Affinity, Expression, and Self-reactivity

Supporting evidence

  • BioPhy-Seq Expression Reflects Native Folding and Trafficking Across Cell Types
Main Claim 2 –

Multidimensional Biophysical Constraints Severely Limit Evolutionary Path Accessibility

Main Claim 3 –

Epistasis Imposes Specific Mutational Order to Navigate Trade-offs

Main Claim 4 –

Conformational Rearrangement Relieves Steric Clashes to Reshape Evolutionary Landscape

Supporting evidence

  • Preconfiguration Makes Mutation Effects Order-dependent, Enabling Path Accessibility

Abstract

Protein evolution is constrained by multidimensional biophysical factors, in which mutations that enhance one property often compromise another. Antibodies represent an extreme case: they evolve rapidly to bind diverse antigens, yet mutations that improve affinity can disrupt folding, reduce cell-surface trafficking, or promote self-reactivity, and are typically selected against during affinity maturation. Though biophysical characterization of individual antibodies suggests that such trade-offs are pervasive, their impact on antibody evolutionary trajectories remains unclear, in part because existing high-throughput biophysical methods rely on heterologous systems that are often poorly suited for human proteins. Here, we develop a high-throughput platform to quantify multiple biophysical parameters of large libraries of full-length proteins that are natively synthesized, processed, and displayed on human cells. We apply this approach to a human antibody lineage that matures to recognize divergent SARS-CoV-2 variants by measuring the surface expression, antigen affinity, and self-reactivity for all 213 possible evolutionary intermediates between the unmutated and mature sequences. These measurements reveal that mutations differentially affect these biophysical properties – in some cases, improving one property at the expense of another. We leverage these data to compute the likelihood of all possible evolutionary paths, finding that very few paths can navigate these multidimensional requirements. The few accessible paths acquire mutations in a specific order that either circumvent trade-offs between biophysical properties or offset deleterious effects on one property with beneficial effects on another. By determining the structures of the ancestral and evolved antibodies, we find that these coordinated mutational effects arise from a conformational rearrangement that alleviates steric clashes and reshapes the biophysical landscape, enabling otherwise inaccessible mutational paths. Together, this work defines the multidimensional biophysical constraints and structural mechanisms that govern antibody evolution and establishes a general framework for mapping and predicting the biophysical effects of mutations in human proteins.

Related papers

How the QED Score works

QED Score is an AI-based quality metric for life science research. It rates each paper on two dimensions: originality (is the finding new and important?) and validity (does the evidence support the claims?). Author names and affiliations are removed before scoring. Each manuscript is broken down into its claims and the experiments behind them, and specialized AI agents then examine those claims for statistical rigor, consistency across figures, and contradictions with the existing literature. A verification layer re-checks every issue they flag. Scores are percentile ranks against all papers in the corpus. In a blinded study of papers where QED Score and journal rank disagreed, domain experts sided with QED Score in 75% of cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?